Retatrutide could be the biggest selling drug ever, Jonah Lupton says

Retatrutide could be the biggest selling drug ever, Jonah Lupton says
HIMS and LLY advance Retatrutide plans

Jonah Lupton, an investor and market commentator, said that HIMS' strengthened partnership with LLY puts the company in a strong position to be among the first to offer Retatrutide once it is approved by the FDA in 2027.

Lupton also stated that, in his opinion, Retatrutide will become the biggest selling drug of all time.

Lupton has recently commented on notable developments in the semiconductor sector. He reported on the 12% drop in MRVL stock following rumors of an MRVL acquisition of LITE. In a separate update, he covered MRVL's agreement to acquire LITE in an all stock transaction valued at $115 billion.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.